Overview

Partners

Partnering | Overview

Heptares is leveraging its transformational StaR® platform to generate a broad and deep pipeline of first-in-class and best-in-class GPCR-targeted medicines. We are focused today on advancing novel drug candidates, both NCEs and antibodies, in the areas of CNS and metabolic disease.

The scope of the opportunity using the Heptares approach extends well beyond our growing pipeline. Large and untapped regions of the GPCR target universe, previously regarded as undruggable, are now tractable for rational drug discovery using the Heptares approach.

We welcome the interest from pharmaceutical and biotechnology companies seeking access to this broader GPCR target landscape through collaboration with Heptares.

Since founding, the Company has established four major collaborations:

  • Four-year collaboration with AstraZeneca (and MedImmune) (2011) focused on developing small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.
  • Exclusive option agreement with Shire (2011) for novel small molecule adensoine A2A anatagonist with best-in-class potential for the treatment of CNS diseases.
  • Approximately $100 million drug discovery collaboration with Takeda (2011) focused on a GPCR linked to CNS disorders.
  • $200 million alliance with the Novartis Option Fund (2009) focused on single GPCR target of strategic interest to Novartis. Novartis and Heptares jointly announced the successful first-ever stabilisation of this previously intractable GPCR using the Heptares technology.

For more information on outlicensing or partnering opportunities, please contact:

Barry Kenny PhD
Chief Business Officer
Heptares Therapeutics

+44 (0)1707 358 628
Contact us

Click on diagram to enlarge